Nephrology & Urology Clinical Trials

Statistical methods in nephrology & urology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All nephrology & urology trials

321 results

• 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1Results postedn = 43NCT03805594
• 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies: Complete Statistical AnalysisIndependent statistical analysis of 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 9NCT04158245
• 2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of 2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 21NCT01821105
• 2-DeoxyglucoseIndependent statistical analysis of A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1/2Results postedn = 12NCT00633087
• 337Independent statistical analysis of BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 1NCT03432897
• 3CIndependent statistical analysis of Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01120028).Phase 2/3Results postedn = 852NCT01120028
• 4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis: Complete Statistical AnalysisIndependent statistical analysis of 4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 72NCT01587898
• 68 Ga-PSMA for High Risk Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of 68 Ga-PSMA for High Risk Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04614363).Phase 1/2Results postedn = 80NCT04614363
• 68Ga PSMA in Preprostatectomy Patients: Complete Statistical AnalysisIndependent statistical analysis of 68Ga PSMA in Preprostatectomy Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03388346).Phase 2/3Results postedn = 22NCT03388346
• 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1/2Results postedn = 10NCT02488070
• A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease: Complete Statistical AnalysisIndependent statistical analysis of A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 154NCT01074125
• A Chatbot Intervention for Reducing HPV Vaccine Hesitancy: Complete Statistical AnalysisIndependent statistical analysis of A Chatbot Intervention for Reducing HPV Vaccine Hesitancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05959564).Phase NAResults postedn = 456NCT05959564
• A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032): Complete Statistical AnalysisIndependent statistical analysis of A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 27NCT06643377
• A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 45NCT00660309
• A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD): Complete Statistical AnalysisIndependent statistical analysis of A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 18NCT05285787
• A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 136NCT00830037
• A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 460NCT00116753
• A Delphi Survey for Key Stakeholders to Identify Priority Self-management Outcomes for Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of A Delphi Survey for Key Stakeholders to Identify Priority Self-management Outcomes for Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 140NCT05991726
• A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.: Complete Statistical AnalysisIndependent statistical analysis of A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06481150).Phase 4Results postedn = 18NCT06481150
• A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1: Complete Statistical AnalysisIndependent statistical analysis of A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1: primary endpoint results,…Phase 1/2Results postedn = 18NCT03837353
• A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 140NCT00510718
• A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen: Complete Statistical AnalysisIndependent statistical analysis of A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1Results postedn = 17NCT00623831
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies: Complete Statistical AnalysisIndependent statistical analysis of A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected…Phase 1/2Results postedn = 222NCT03829501
• A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy: primary endpoint…Phase 2Results postedn = 226NCT01712061
• A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 20NCT02019693
• A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 108NCT00466440
• A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 105NCT01667536
• A Phase 2b Diabetic Kidney Disease Study: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2b Diabetic Kidney Disease Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04170543).Phase 2Results postedn = 609NCT04170543
• A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis: Complete Statistical AnalysisIndependent statistical analysis of A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 432NCT02504294
• A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 22NCT02849990
• A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 72NCT02059213
• A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC): Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 74NCT00726323
• A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 30NCT00523640
• A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS): Complete Statistical AnalysisIndependent statistical analysis of A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS): primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 17NCT02000440
• A Pilot Clinical Trial of TENA Identifi in the Nursing Home Setting: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Clinical Trial of TENA Identifi in the Nursing Home Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 49NCT03209570
• A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 16NCT01084759
• A Pilot Study to Assess Effects of Self-Administered Nitrous Oxide (SANO) on Urodynamic Study (UDS) Parameters: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study to Assess Effects of Self-Administered Nitrous Oxide (SANO) on Urodynamic Study (UDS) Parameters: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 4Results postedn = 19NCT05883332
• A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 19NCT02142608
• A Prospective, Single-center, Single-arm, Pivotal Trial of the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System: Complete Statistical AnalysisIndependent statistical analysis of A Prospective, Single-center, Single-arm, Pivotal Trial of the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 42NCT05715827
• A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome: Complete Statistical AnalysisIndependent statistical analysis of A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 131NCT02411110
• A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD): Complete Statistical AnalysisIndependent statistical analysis of A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 55NCT00648167
• A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 114NCT02499497
• A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms: Complete Statistical AnalysisIndependent statistical analysis of A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced…Phase 4Results postedn = 30NCT00658333
• A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia: Complete Statistical AnalysisIndependent statistical analysis of A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 1/2Results postedn = 61NCT00894517
• A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 1/2Results postedn = 52NCT03241173
• A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria: Complete Statistical AnalysisIndependent statistical analysis of A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 154NCT01847092
• A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based: Complete Statistical AnalysisIndependent statistical analysis of A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 446NCT01820572
• A Study in Participants With Diabetic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study in Participants With Diabetic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01113801).Phase 2Results postedn = 417NCT01113801
• A Study of AA4500 in Men With Peyronie’s Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study of AA4500 in Men With Peyronie's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01243411).Phase 3Results postedn = 348NCT01243411
• A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 133NCT02639182

← All therapeutic areas